Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (April 2023)
18 slides from Enveric Biosciences's investor presentation, Apr 13, 2023
Slide 1: Corporate Presentation Q2 2023
id SINVYSIRIC « taraneane BIOSEIENCES CORPORATE PRESENTATION Q2 2023
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does net constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Enveric Biosciences is a biotechnology company
Enveric Biosciences is a biotechnology company dedicated to the development of novel small- molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Our mission is to pioneer new and innovative solutions with the potential to have profound effects on patients and their
Slide 4: Executive Summary
Executive Summary Enveric Biosciences (NASDAQ: ENVB) + Comprised of a team of experienced CNS drug developers who have successfully led wy programs from inception to market approval + Drug platform that has created 500+ New Chemical Entities to date, intended to deliver led greater benefits to patie
Slide 5: Executing with Experience and Passion: Pharma & Bio Leadership
Executing with Experience and Passion: Pharma & Bio Leadership Dr. Joseph Tucker Mr-avaniKanubadél Dr. Bob Dagher Mr. kevin Coveney Dr. Peter Facchini Dr-Ricktight Dr.Kevintecch Chief executive President & Chief Chief Medicar officer [Ml chietFinancial Officer | chief innovation Oficer [Vice-Preside
Slide 6: Anxiety Continues to be a Tremendous Unmet Need with Limited Innovation in Nearly Two Decades
Anxiety Continues to be a Tremendous Unmet Need with Limited Innovation in Nearly Two Decades + Anxiety disorders are among the most common CNS Disorders, ranking second. + Anxiety disorders are chronic conditions that remain poorly controlled despite available treatments. + The last FDA-approved dr
Slide 7: Advancing Psychedelic Compounds in the Treatment of Mental Health
Advancing Psychedelic Compounds in the Treatment of Mental Health 1st Generation Psilocybin: Enveric’s Psychedelic-Inspired Therapies + Currently under investigation + Multiple, novel molecules in development with EB-373 + Challenges with patentability ready to enter clinic 9 . Pe 7 Y . + Establishe
Slide 8: Proprietary Discovery Platform - Psybrary + PsyAI
PROPRIETARY DISCOVERY PLATFORM - Psybrary™ + PsyAl + Combines synthetic biology and traditional chemistry techniques to create a library of molecules that is larger and more diverse than what chemistry techniques alone can achieve PSYBRARY™ PSYAI * Machine-learning models combined with 3D. structure
Slide 9: Two Separate Series of Differentiated Assets for Mental Health Indications
Two Separate Series of Differentiated Assets for Mental Health Indications PROGRAM SCOVERY PRE-CLINICAL PHASET PHASE 2 PHASE3 NEXT MILESTONE EVM201 SERIES - Next Generation Synthetic Psilocybin Analogues 73 Initiate Phase I Trial Anxiety Disorder (942023) Lead Selection (Q4 2023)
Slide 10: Next generation synthetic psilocybin analogues
Next generation synthetic psilocybin analogues Rationally designed prodrugs of the active metabolite: psilocin Altered metabolic and pharmacokinetic properties to achieve improved tisk/benefit profile OPTIMIZED DELIVERY ROUTE y¥ Can be administered via oral, intra-nasal, buccal or intravenous route
Slide 11: EVM201 Molecules release psilocin and Produce Modulated Response in Animal Model of Hallucination
EVM201 Molecules release psilocin and Produce Modulated Response in Animal Model of Hallucination EVM201 molecules, at different dose levels and brain exposures, produce consistent level of 5-HT2A-mediated Head Twitch Response in mice #HTR assessed during the 15-30 min window post-administration + H
Slide 12: Marble Burying: a pharmacodynamic mouse model of anxiety disorders
Marble Burying: a pharmacodynamic mouse model that measures aspects reflective of anxiety disorders in human A Single Dose of Day 1 .<0.001 Day 7 (p=e00%5] EVM201 Demonstrates p= 0.0006 2000 100 nee 0.0000 Complete = = a. (2 N Rescue of Anxiety = = in Stressed 75 3 3 k? Ts J Animal Model on a 8 oo]
Slide 13: EB-373 Lead Product Candidate for the Treatment of Anxiety Disorder
EB-373 Lead Product Candidate for the Treatment of Anxiety Disorder New Chemical Entity v Next generation synthetic psilocin prodrug v Recognized as NCE by Australia’s Therapeutic Goods Administration (TGA) Clinical Development Strategy y¥ Phase | clinical trial expected to initiate in Q4 2023 ¥ Tri
Slide 14: EVM301 Series
EVM301 Series GEN-3’s Innovative Approach for Treating Mental Health Diseases MAXIMIZING THERAPEUTIC EFFECT New molecular entities designed to hit multiple receptors in the serotonin family simultaneously Targeting subset of serotonin receptors along with synergistic effects on other brain receptor
Slide 15: Enveric Intellectual Property
Enveric Intellectual Property Three Moats Protecting Enveric’s Strong Intellectual Property Inner Moat Second Moat Outer Moat + 5S years New + Submitted 15+ patent + IP Discovery Chemical Entity applications covering Platform, (NCE) and 3 years EVM201 & EVM301. New Clinical Study + Psybrary™ and (NC
Slide 16: Development timeline 2022-2024
2022 2023 2024 Ql Q2 Q3 Q4 Ql Q2 Q3 Q4 eiclee Australia subsidiary, CRO partner; trial site ctior preparation EVM301 SERIES In-vitro, In-vivo Lead Selection Testing Target Psybrary Molecule Lead Candidate IND Enabling Nomination Studies Product Screening Design 16
Slide 17: Enveric Biosciences is a biotechnology company
[4 Nasdaq :ENVB Enveric Biosciences is a biotechnology company dedicated to the development of novel small- molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Experienced Team + Team of experienced CNS drug developers who have successfully led programs from incep
Slide 18: Thank you!
id SINVYSIRIC « taraneane BIOSEIENCES Thank you!
Enveric Biosciences — Investor Presentation (April 2023) on 6ix